Su1200 Sensitivity of Lennard-Jones Criteria in the Diagnosis of Crohn's Disease

Abstract

that ficolin-2 serum levels were significantly higher in Crohn’s disease (CD) patients compared to healthy controls. Of note, no difference was found regarding serum ficolin-2 levels when comparing patients with ulcerative colitis to healthy controls. We aimed to evaluate serum ficolin-2 concentrations in CD patients regarding their correlation with endoscopic severity and to compare them with clinical activity, fecal calprotectin, and CRP. Methods: Patients provided fecal and blood samples before undergoing ileo-colonoscopy. Disease activity was scored clinically according to the Harvey Bradshaw Index (HBI) and endoscopically according to the simplified endoscopic score for CD (SES-CD). Ficolin-2 serum levels and fecal calprotectin levels were measured by ELISA. Results: A total of 136 CD patients were prospectively included (mean age at inclusion 41.5±15.4 years, 37.5% females). Median HBI was 3 [2 6] points, median SES-CD was 5 [2 8], median fecal calprotectin was 300 [120 703] mg/g, and median serum ficolin-2 was 2.69 [2.02 3.83] mg/mL. The SES-CD score correlated significantly with fecal calprotectin levels (r = 0.639, p < 0.001), CRP (r = 0.444, p < 0.001), and the HBI (r = 0.363, p < 0.001), whereas only a weak correlation was found with ficolin-2 serum levels (r = 0.144, p = 0.094). Ficolin-2 serum levels were higher in CD patients with mild endoscopic disease compared to patients in endoscopic remission (p = 0.021) but no difference in ficolin-2 serum levels was found between patients with mild, moderate, and severe endoscopic disease. Conclusions: Ficolin-2 serum levels correlate worse with endoscopic CD activity when compared to fecal calprotectin, CRP or Harvey Bradshaw index. Ficolin-2 serum levels will probably not have a future role as biomarkers to monitor endoscopic CD activity.